Loading...
Protalix BioTherapeutics Community
NYSEAM:PLX Community- 2 Narratives written by author
- 1 Comments on narratives written by author
- 73 Fair Values set on narratives written by author
Community Investing Ideas
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
ZW
US$4.23
47.5% undervalued intrinsic discount
Zwfis Fair Value
Revenue growth
14% p.a.
Profit Margin
20%
Future PE
29.15x
Share price in 2028
US$5.11
EMA Reviews And Rare Disease Trends Will Open Global Markets
Key Takeaways Commercialization and regulatory expansion of Elfabrio, along with pipeline growth, position Protalix for recurring revenue growth and improved patient retention. Platform scalability and partner contracts enhance profitability and offer substantial upside through royalty and milestone payment opportunities.Read more
2users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AN
US$14
84.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
44.92% p.a.
Profit Margin
70.06%
Future PE
12.51x
Share price in 2028
US$16.33